# ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

> **NCT01997840** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 103 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone

## Key facts

- **NCT ID:** NCT01997840
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03-01
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-02-29
- **Target enrollment:** 103 (ACTUAL)
- **Why stopped:** Change in business priorities.
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01997840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01997840, "ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01997840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*